325 related articles for article (PubMed ID: 30415110)
1. Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience.
Guevara-Cuellar CA; Parody-Rúa E; Garcia-Perdomo HA; Arenas-Duque A
Value Health Reg Issues; 2018 Dec; 17():174-182. PubMed ID: 30415110
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK.
Walker A; Doyle S; Posnett J; Hunjan M
BJU Int; 2013 Sep; 112(5):638-46. PubMed ID: 23356792
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
Ohsfeldt RL; Kreder KJ; Klein RW; Chrischilles EA
J Manag Care Pharm; 2004; 10(5):412-22. PubMed ID: 15369424
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia--The Markov model based on data from Montenegro.
Dabanović V; Kostić M; Janković S
Vojnosanit Pregl; 2016 Jan; 73(1):26-33. PubMed ID: 26964381
[TBL] [Abstract][Full Text] [Related]
5. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
McDonald H; Hux M; Brisson M; Bernard L; Nickel JC
Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
[TBL] [Abstract][Full Text] [Related]
6. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF
J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of medical treatment of benign prostatic hyperplasia in the Brazilian public health system.
Bahia LR; Araujo DV; Pepe C; Trindade M; Camargo CM; Javaroni V
Int Braz J Urol; 2012; 38(5):595-605. PubMed ID: 23131517
[TBL] [Abstract][Full Text] [Related]
8. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
DiSantostefano RL; Biddle AK; Lavelle JP
Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
[TBL] [Abstract][Full Text] [Related]
9. Finasteride for benign prostatic hyperplasia.
Tacklind J; Fink HA; Macdonald R; Rutks I; Wilt TJ
Cochrane Database Syst Rev; 2010 Oct; 2010(10):CD006015. PubMed ID: 20927745
[TBL] [Abstract][Full Text] [Related]
10. [Cost-effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain].
Antoñanzas F; Brenes F; Molero JM; Fernández-Pro A; Huerta A; Palencia R; Cozar JM
Actas Urol Esp; 2011 Feb; 35(2):65-71. PubMed ID: 21269736
[TBL] [Abstract][Full Text] [Related]
11. Re: an economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
DiSantostefano RL; Biddle AK; Lavelle JP
Can J Urol; 2005 Feb; 12(1):2508-9; author reply 2509-10. PubMed ID: 15777487
[No Abstract] [Full Text] [Related]
12. Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial.
Kaplan SA; Lee JY; Meehan AG; Kusek JW
J Urol; 2016 Jun; 195(6):1825-9. PubMed ID: 26678956
[TBL] [Abstract][Full Text] [Related]
13. A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model.
Udeh EI; Ofoha CG; Adewole DA; Nnabugwu II
BMC Cancer; 2016 Jul; 16():405. PubMed ID: 27388750
[TBL] [Abstract][Full Text] [Related]
14. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Logan YT; Belgeri MT
Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial.
Bjerklund Johansen TE; Baker TM; Black LK
BJU Int; 2012 Mar; 109(5):731-8. PubMed ID: 21933326
[TBL] [Abstract][Full Text] [Related]
16. [Comment to: «Cost-Effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain»].
Miñana B
Actas Urol Esp; 2011 Feb; 35(2):72. PubMed ID: 21324551
[No Abstract] [Full Text] [Related]
17. Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial.
Gupta N; Rogers T; Holland B; Helo S; Dynda D; McVary KT
J Urol; 2018 Aug; 200(2):405-413. PubMed ID: 29499208
[TBL] [Abstract][Full Text] [Related]
18. Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia.
Bhardwa J; Goldstraw M; Tzortzis S; Kirby R
Expert Opin Pharmacother; 2007 Jun; 8(9):1337-44. PubMed ID: 17563267
[TBL] [Abstract][Full Text] [Related]
19. Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.
Doggrell SA
Expert Opin Pharmacother; 2004 May; 5(5):1209-11. PubMed ID: 15155119
[TBL] [Abstract][Full Text] [Related]
20. Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia?
McVary KT; Rogers T; Mahon J; Gupta NK
J Sex Med; 2018 Dec; 15(12):1728-1738. PubMed ID: 30446471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
